United Therapeutics EVP executes 10b5-1 sale of 11,000 shares
Rhea-AI Filing Summary
United Therapeutics (UTHR) Form 4: EVP & General Counsel Paul A. Mahon exercised 11,000 stock options at an exercise price of $135.42 on 07/24/2025, converting them into common shares. The same day, he disposed of the entire 11,000-share lot through three open-market sales executed under a pre-arranged Rule 10b5-1 plan at weighted-average prices of $303.31, $304.25 and $305.14, generating gross proceeds of roughly $3.3 million and a spread of about $168 per share over the strike price.
Following the transactions Mahon retains 36,781 shares of common stock held directly and continues to hold 99,000 unexercised options (same grant, expiring 03/15/2027). No other classes of securities were affected.
The filing represents routine insider activity disclosed within two business days and does not alter company guidance or fundamentals. Investors often monitor insider sales for sentiment signals; however, the use of a 10b5-1 plan and the retention of a sizable equity stake temper any negative inference.
Positive
- Retention of 36,781 shares and 99,000 options indicates the executive maintains meaningful exposure to UTHR’s equity upside.
Negative
- Sale of entire 11,000 shares immediately after exercise may be interpreted by some investors as short-term profit-taking, although mitigated by 10b5-1 plan.
Insights
TL;DR: Pre-planned option exercise & sales; neutral signal given retained stake and 10b5-1 plan.
The $3.3 m sale equates to ≈0.08 % of UTHR’s ≈13.9 m outstanding shares, thus has negligible dilution or float impact. Mahon still holds nearly 37 k shares plus 99 k options, implying continued alignment with shareholders. Because the trade was executed via an established 10b5-1 plan, it likely reflects liquidity or tax planning rather than valuation concerns. I view the event as non-impactful to earnings outlook or valuation multiples.
TL;DR: Compliance appears robust; transaction consistent with best-practice disclosures.
Filing timings meet Section 16(a) requirements, and the weighted-average price disclosures satisfy SEC guidance for aggregated sales. The sizeable remaining option position suggests long-term incentive alignment. No red flags such as clustered insider selling or unexplained amendments are present. Governance impact: neutral.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 11,000 | $0.00 | -- |
| Exercise | Common Stock | 11,000 | $135.42 | $1.49M |
| Sale | Common Stock | 3,769 | $303.3063 | $1.14M |
| Sale | Common Stock | 4,977 | $304.2532 | $1.51M |
| Sale | Common Stock | 2,254 | $305.1444 | $688K |
Footnotes (1)
- This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on December 24, 2024. This transaction was executed in multiple trades at prices ranging from $302.77 to $303.73. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $303.78 to $304.77. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $304.78 to $305.50. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
